Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
X antigen family member 2 (XAGE2)
- Target
- XAGE2
- Molecular classification
- Cancer-testis antigen, Protein (non-enzymatic), Tumor-associated antigen
01
Overview
X antigen family member 2 (XAGE2) is a member of the XAGE subfamily within the GAGE cancer-testis antigen family. XAGE2 is primarily expressed in normal testicular tissue but is also found in a range of tumors, including Ewing’s sarcoma, rhabdomyosarcoma, breast cancer, and germ cell tumors[1][3][6]. It is part of a broader class of cancer-testis (CT) antigens, which are largely restricted to germ cells in the testis and certain malignancies, making them attractive candidates for cancer immunotherapy and as potential biomarkers. Like related GAGE/XAGE antigens, its main functions are believed to involve immune recognition and a possible role in supporting tumor cell proliferation and survival, though the exact cellular mechanisms for XAGE2 remain poorly described[1][4][6]. There are currently no approved drugs targeting XAGE2 directly, but it is being considered for vaccine and immunotherapy development due to its cancer-restricted expression profile[6].
- Other names
- GAGED3XAGE-2CT12.2XAGE2BCancer/testis antigen 12.2G antigen family D member 3cancer/testis antigen family 12, member 2
02
Mechanism of action
Immune-mediated recognition or targeting (potential immunotherapy target as a cancer-testis antigen)
03
Biological functions
Immune response (antigen recognized by immune system)Potential role in cell proliferation and survival (by analogy to other GAGE/XAGE family members)Other (function in normal tissue not fully clear, mainly testicular expression)
04
Disease associations
Cancer (expression in various tumors: Ewing’s sarcoma, rhabdomyosarcoma, breast cancer, germ cell tumor)
05
Safety considerations
Potential risk of off-tumor toxicity when used as an immunotherapy target (due to expression in testes and possibly other reproductive tissues, though generally not in most normal adult somatic tissues)
06
Biomarkers
Marker for cancer diagnosis or prognosis (pending confirmation; expression in tumors vs normal tissues makes it a candidate biomarker)
Beyond the preview
Go deeper on X antigen family member 2 (XAGE2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on X antigen family member 2 (XAGE2).